Operationalizing Checkpoint Inhibitors in Urologic Practice Webcast (2022)

Checkpoint inhibitors (CPIs) are increasingly being utilized in the treatment of urinary tract cancers, with several approvals in metastatic and now localized disease states. Urologists are embracing these therapies and contemplating bringing them into their own clinics and practices. Centralizing patients’ oncologic care, simplifying combination treatment strategies, and providing value-based and efficient cancer care are major reasons to begin administering CPIs for urologists. This course will discuss and provide a structured approach to incorporating checkpoint inhibitors in a busy urologic practice. The course is divided in 3 major sections: indications and introduction; building an immuno-oncology (IO) program; and clinical monitoring/side effect management. Attendees will gain a overall understanding of the clinical facets of caring for patients on immunotherapy as well as infrastructure and personnel requirements for program support. Specific attention will be given to logistical issues such as patient navigation and education, infusion workflow, and financial/economic practice considerations. A case-based section on adverse effect management will be presented with key take home messages to improve urologist comfort surrounding this issue.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

Astellas
AstraZeneca
Bristol Myers Squibb
Exact Sciences
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.
Pfizer, Inc.
Sanofi Genzyme

Target Audience

  • Urologists
  • Residents

Learning Objectives

At the conclusion of this course, participants will be able to:

  1. Discuss how to develop a structured approach for administering checkpoint inhibitors in urologic practice as part of a structured program.
  2. Manage adverse events from checkpoint inhibitors
  3. Identify practice implications of implementing a checkpoint inhibitor program
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
05/18/2022
Course expires: 
05/18/2023
Rating: 
0

Education Council Disclosures

 Education Council Disclosures 2021

COI Review Work Group Disclosures

 COI Review Work Group Disclosures 2021

All relevant financial relationships have been mitigated. 

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Gautam Jayram, MD

has a financial relationship (Consultant or Advisor (Oncology)) with UroGPO;.
has a financial relationship (Consultant or Advisor (Oncology)) with Photocure;.
has a financial relationship (Consultant or Advisor (Oncology)) with Merck;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bristol Myers Squibb;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tempus;.
has a financial relationship (Consultant or Advisor (Oncology)) with Exact Sciences;.
has a financial relationship (Consultant or Advisor (Oncology)) with Blue Earth;.
has a financial relationship (Consultant or Advisor (Oncology)) with AstraZeneca;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Janssen;.
Faculty(s)

Gordon Brown, DO

has a financial relationship (Consultant or Advisor (Oncology)) with pfizer;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Watson ;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Sanofi-Aventis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astellas;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Johnson and Johnson;.
has a financial relationship (Consultant or Advisor (Oncology)) with merck;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Genomic Health;.

Neal Shore, MD

has a financial relationship (Consultant or Advisor (Oncology)) with Boston Scientific;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant;.
has a financial relationship (Consultant or Advisor (Oncology)) with Urogen;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Merck;.
has a financial relationship (Consultant or Advisor (Oncology)) with Genesis Care;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Tolmar;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pacific Edge;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Propella;.
has a financial relationship (Consultant or Advisor (Oncology)) with Foundation Medicine;.
has a financial relationship (Consultant or Advisor (Oncology)) with Clovis Oncology;.
has a financial relationship (Consultant or Advisor (Oncology)) with Abbvie;.
has a financial relationship (Consultant or Advisor (Oncology)) with Guardant;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Astra Zeneca;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Phosphorus;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Bayer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Sanofi Genzyme;.
has a financial relationship (Consultant or Advisor (Oncology)) with GConcology;.
has a financial relationship (Consultant or Advisor (Oncology)) with Amgen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Genomic Health;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Genentech;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with emdSeronoMerck;.
has a financial relationship (Consultant or Advisor (Oncology)) with Urogen;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Myriad;.
has a financial relationship (Consultant or Advisor (Oncology)) with Sesen Bio;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Astellas;.
has a financial relationship (Consultant or Advisor (Oncology)) with Invitae;.
has a financial relationship (Consultant or Advisor (Oncology)) with Exact Imaging;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bristol Myers Squibb;.
has a financial relationship (Consultant or Advisor (Oncology)) with Moivant;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with AstraZeneca;.
has a financial relationship (Consultant or Advisor (Oncology)) with Cold Genesys;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with MDxHealth;.
has a financial relationship (Consultant or Advisor (Oncology)) with Exact Sciences;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Nymox;.
has a financial relationship (Consultant or Advisor (Oncology)) with FerGene;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by viewing the webcast, completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2022
Expiration Date: May, 2023

ACCREDIDATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY:

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group. 
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning 
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES

DISCLAIMER:

 The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

CONSENT TO USE OF PHOTOGRAPHIC IMAGES:

Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

REPRODUCTION PERMISSION:

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

SPECIAL ASSISTANCE/ DIETARY NEEDS:

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.